The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection.

Abstract:

:There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defined in HIV-HBV-coinfected individuals and might directly alter pathogenesis. In addition, an impaired HBV-specific T-cell immune response is likely to be important. The roles of microbial translocation, immune activation and increased hepatic stellate cell activation will be important areas for future study.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Iser DM,Lewin SR

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

155-64

issue

2

eissn

1359-6535

issn

2040-2058

journal_volume

14

pub_type

杂志文章,评审
  • Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.

    abstract:BACKGROUND:We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir. METHODS:This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) al...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP1506

    authors: Dingemanse J,van Giersbergen PL,Patat A,Nilsson PN

    更新日期:2010-01-01 00:00:00

  • Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.

    abstract::The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Matsumoto K,Ogawa N,Nerome K,Numazaki Y,Kawakami Y,Shirato K,Arakawa M,Kudoh S,Shimokata K,Nakajima S,Yamakido M,Kashiwagi S,Nagatake T

    更新日期:1999-01-01 00:00:00

  • Viral hepatitis and HIV: update and management.

    abstract::HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2601

    authors: Núñez M,Mendes-Correa MC

    更新日期:2013-01-01 00:00:00

  • Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.

    abstract:BACKGROUND:The multidrug resistance proteins (MRPs) form a subfamily within the ATP binding cassette transporters that confer resistance to a variety of structurally unrelated compounds. MRP4 has been reported to transport antiretroviral drugs out of cells in an active process. Although the main therapeutic effects of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1468

    authors: Clemente MI,Alvarez S,Serramía MJ,Turriziani O,Genebat M,Leal M,Fresno M,Muñoz-Fernández MA

    更新日期:2009-01-01 00:00:00

  • Preventing and treating secondary bacterial infections with antiviral agents.

    abstract::Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1730

    authors: McCullers JA

    更新日期:2011-01-01 00:00:00

  • In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.

    abstract::The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Kosmiski LA,Miller HL,Klemm DJ

    更新日期:2006-01-01 00:00:00

  • Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

    abstract:BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therap...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP3169

    authors: Lee SH,Cheon GJ,Kim HS,Kim SG,Kim YS,Jeong SW,Jang JY,Kim BS,Jun BG,Don Kim Y,Jun DW,Sohn JH,Kim TY,Lee BS

    更新日期:2018-01-01 00:00:00

  • Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

    abstract:BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

    更新日期:2003-02-01 00:00:00

  • The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.

    abstract::HIV drug resistance remains one of the most important influences on long-term therapeutic prospects. Resistance and therapeutic failure arises out of the selection and preservation of randomly generated genomic mutations that confer a replicative advantage in the presence of one or more antiretrovirals. The primary co...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Pillay D

    更新日期:2001-01-01 00:00:00

  • Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

    abstract:BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3851/IMP3205

    authors: Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

    更新日期:2018-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP2358

    authors: Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期:2013-01-01 00:00:00

  • Altered heterochromatin organization after perinatal exposure to zidovudine.

    abstract:BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Senda S,Blanche S,Costagliola D,Cibert C,Nigon F,Firtion G,Floch C,Parat S,Viegas-Péquignot E

    更新日期:2007-01-01 00:00:00

  • Factors associated with HBV virological breakthrough.

    abstract:BACKGROUND:Little is known about non-adherence to HBV therapy. This study aimed to investigate the relationship between self-reported missed days of antiviral therapy and HBV virological breakthrough and factors associated with virological breakthrough. METHODS:A cross-sectional survey of 211 HBV patients receiving or...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP3087

    authors: Sheppard-Law S,Zablotska-Manos I,Kermeen M,Holdaway S,Lee A,Zekry A,Dore GJ,George J,Maher L

    更新日期:2017-01-01 00:00:00

  • Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.

    abstract:BACKGROUND:Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immu...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Wiegand J,Cornberg M,Aslan N,Schlaphoff V,Sarrazin C,Kubitschke A,Buggisch P,Ciner A,Jaeckel E,Manns MP,Wedemeyer H

    更新日期:2007-01-01 00:00:00

  • The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs.

    abstract:BACKGROUND:Studies of the effects of antiretroviral drugs on lipid metabolism are limited by the availability of suitable models. We have thus developed an animal model utilising Göttingen mini-pigs. The normal lipid metabolism of mini-pigs closely reflects that of humans and they are expected to have similar reactions...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1509

    authors: Petersen E,Mu H,Porsgaard T,Bertelsen LS

    更新日期:2010-01-01 00:00:00

  • Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

    abstract::Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP3245

    authors: Forton D,Weissenborn K,Bondin M,Cacoub P

    更新日期:2018-01-01 00:00:00

  • Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.

    abstract:BACKGROUND:Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations. METHODS:We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion i...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1751

    authors: Walczak M,Regts J,van Oosterhout AJ,Boon L,Wilschut J,Nijman HW,Daemen T

    更新日期:2011-01-01 00:00:00

  • Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

    abstract:BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP1931

    authors: Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

    更新日期:2011-01-01 00:00:00

  • HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

    abstract::The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2951

    authors: Marra CM

    更新日期:2015-01-01 00:00:00

  • Ribavirin considerations in treatment optimization.

    abstract::Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Dusheiko G,Nelson D,Reddy KR

    更新日期:2008-01-01 00:00:00

  • Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.

    abstract:BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3028

    authors: Drouot E,Piret J,Boivin G

    更新日期:2016-01-01 00:00:00

  • Maternal antiretroviral prophylaxis and breastfeeding.

    abstract::The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breast...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP2314

    authors: Marzolini C,Gray GE

    更新日期:2012-01-01 00:00:00

  • Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.

    abstract:BACKGROUND:Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV treatments often include dolutegravir, raltegravir, rilpivirine or cobicistat, which inhibit the prox...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3373

    authors: Brunet L,Wyatt C,Hsu R,Mounzer K,Fusco J,Fusco G

    更新日期:2020-11-19 00:00:00

  • Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

    abstract:BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Laufer N,Laguno M,Perez I,Cifuentes C,Murillas J,Vidal F,Bonet L,Veloso S,Gatell JM,Mallolas J

    更新日期:2008-01-01 00:00:00

  • A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.

    abstract:BACKGROUND:Lamivudine (3TC) therapy can cause the emergence of M1841/V. Previous studies suggest a higher fidelity of the mutant reverse transcriptase and lower replication capacity of the mutant virus. No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:

    authors: Fox Z,Dragsted UB,Gerstoft J,Phillips AN,Kjaer J,Mathiesen L,Youle M,Katlama C,Hill A,Bruun JN,Clumeck N,Dellamonica P,Lundgren JD,COLATE study group.

    更新日期:2006-01-01 00:00:00

  • P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

    abstract:BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1399

    authors: Janneh O,Anwar T,Jungbauer C,Kopp S,Khoo SH,Back DJ,Chiba P

    更新日期:2009-01-01 00:00:00

  • Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

    abstract:BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2722

    authors: Gutierrez-Valencia A,Torres-Cornejo A,BenMarzouk-Hidalgo OJ,Ruiz-Valderas R,Lluch A,Viciana P,López-Cortés LF

    更新日期:2014-01-01 00:00:00

  • Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.

    abstract:BACKGROUND:Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. METHODS:A total of 2...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP1696

    authors: Su TH,Hsu CS,Chen CL,Liu CH,Huang YW,Tseng TC,Liu CJ,Chen PJ,Lai MY,Chen DS,Kao JH

    更新日期:2010-01-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract:BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3197

    authors: Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期:2018-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2612

    authors: Archambault J,Melendy T

    更新日期:2013-01-01 00:00:00